Mobile website
Archive > Volume 23 Issue 3 > 2016,23(3):403-407. DOI:10.3872/j.issn.1007-385X.2016.03.019 Prev Next
Clinical Research
Clinical efficacy of DC-CIK cell combined with chemotherapy in treatment of extensive-stage small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the safety and efficacy of dentritic cell (DC)-cytokine induced killer cells(CIKs) immune therapy combined with chemotherapy in treatment of extensive-stage small cell lung cancer(SCLC). Methods：Fifteen extensive-stage SCLC patients, who were admitted to Shanghai Eastern Hepatobiliary Surgery Hospital from June 2012 to January 2015，received DC-CIKs immune therapy after 3-5 days of EP chemotherapy（VP16+DDP)，three weeks for one cycle. The changes in T cell subsets in peripheral blood of patients before and after the combined treatment, clinical efficacy, life quality, and adverse events were observed. Results：All the 15 patients responded to the combined treatment，among them, 3 achieved CR，8 cases of PR，3 cases of SD and 1 cases of PD. The response rate (RR) and disease control rate (DCR) were 73.3% and 93.3%, respectively. The median progression free survival (PFS) and overall survival (OS) was 6.8 months and 14.9 months, respectively. The OS of the two patients obtained CR was 29.1 months and 37.2 months, respectively. Compared to pre-treatment, regulatory T cell (Treg) and CD4+T cells decreased（ \[5.42±0.70\]% vs \[6.16±0.77\]%，P<0.05；\[28.74±1.92\]% vs \[33.06±2.69\]%，P<0.05)，〖JP2〗while CIKs and CD8+T cells increased （\[5.58±0.94\]% vs \[4.94±0.77\]%，P<0.05；\[43.26±3.87\]% vs \[39.92±2.78\]%，P<0.01) after the combined treatment，and the CD4+/CD8+T cells ratio declined significantly (\[0.67±0.09\]% vs \[0.83±0.10\]%，P<0.01). 2 patients improved with 20 scores and 9 improved with 10 scores in KPS evaluation with a effective rate of 73.3%. The side effects mainly were mild myelosuppression and gastrointestinal reaction，patients could recover after symptomatic treatment.Conclusion：DC-CIK combined with chemotherapy can improve the clinical remission rate of extensive-stage SCLC, prolong the survival time, and improve quality of life and immune function, it is safe and effective that deserves further study．
Keywords:
Project Supported:
Project supported by Mayor National Science and Technology Project of China（No.2013ZX10002-010-007）
Clc Number:
